MedTrace Logo

Study of Theories About Myopia Progression (STAMP)

NCT00335049 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2022-10-28

No results posted yet for this study

Summary

At this time, we do not know what causes a child to become more nearsighted (myopic). STAMP will help us better understand nearsightedness in children. Children will be randomly chosen to wear regular glasses (single vision lenses) or no-line bifocal glasses (progressive addition lenses) for the first year of the study. All children will wear regular glasses for the second year of the study. STAMP will compare how the eye changes shape in the two groups to help us understand why children become nearsighted. The two theories of myopia progression that are being evaluated are based on different factors. One theory is based on environmental factors such as extended near work while the other theory is based on genetically coded factors.

Conditions

  • Myopia

Interventions

DEVICE

progressive addition spectacle lens (bifocal)

Progressive addition lenses (PAL) with a +2.00 D add.

DEVICE

Single Vision Lenses (SVLs)

Single vision spectacle lenses.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Ohio State University

    lead OTHER

Principal Investigators

  • David A Berntsen, OD, PhD · University of Houston

  • Karla Zadnik, OD, PhD · Ohio State University

  • Donald O Mutti, OD, PhD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335049 on ClinicalTrials.gov